Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma

Thyroid

Volumn 27, Issue 5, 2017, Pages 672-681

  Rao, Sarika N ^a   Zafereo, Mark ^a   Dadu, Ramona ^a   Busaidy, Naifa L ^a   Hess, Kenneth ^a   Cote, Gilbert J ^a   Williams, Michelle D ^a   William, William N ^a   Sandulache, Vlad ^a   Gross, Neil ^a   Gunn, G Brandon ^a   Lu, Charles ^a   Ferrarotto, Renata ^a   Lai, Stephen Y ^a   Cabanillas, Maria E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anaplastic thyroid cancer; BRAF; chemotherapy; p53; radiation; thyroid surgery; undifferentiated

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CYTOTOXIC AGENT; DABRAFENIB; IMMUNOMODULATING AGENT; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN P53; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; TRAMETINIB;

ADULT; ANAPLASTIC THYROID CANCER; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL OUTCOME; CONTROLLED STUDY; DISTANT METASTASIS; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; REFERENCE VALUE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOMATIC MUTATION; SYSTEMIC THERAPY; THYROIDECTOMY; TIME TO TREATMENT; TREATMENT FAILURE; AGED; MORTALITY; SURVIVAL RATE; THYROID CARCINOMA; THYROID TUMOR; TIME FACTOR;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TREATMENT FAILURE;

EID: 85018322461     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2016.0395     Document Type: Article

References (30)

1. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM, American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce 2012 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104-1139
2. Giuffrida D, Gharib H 2000 Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11:1083-1089
3. Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R 2016 Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract 12:511-518
4. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K 2011 Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21:1183-1189
5. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335
6. Keutgen XM, Sadowski SM, Kebebew E 2015 Management of anaplastic thyroid cancer. Gland Surg 4:44-51
7. Aslan ZA, Granados-Garcia M, Luna-Ortiz K, Guerrero-Huerta FJ, Gomez-Pedraza A, Namendys-Silva SA,Meneses-Garcia A, Ordonez-Mosquera JM 2014 Anaplastic thyroid cancer: multimodal treatment results. Ecancermedicalscience 8:449
8. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, MOrrow M 2002 AJCC cancer staging manual, 6th edition. Springer, New York
9. Brignardello E, Palestini N, Felicetti F, Castiglione A, Piovesan A, Gallo M, Freddi M, Ricardi U, Gasparri G, Ciccone G, Arvat E, Boccuzzi G 2014 Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid 24:1600-1606
10. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034
11. Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL 2003 Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 27:1559-1564
12. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335-2342
13. Swaak-Kragten AT, Wilt JH, Schmitz PI, Bontenbal M, Levendag PC 2009 Multimodality treatment for anaplastic thyroid carcinoma-treatment outcome in 75 patients. Radiother Oncol 92:100-104
14. Yoshida A, Sugino K, Sugitani I, Miyauchi A 2014 Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination. World J Surg 38:2311-2316
15. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC 2011 Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21:25-30
16. Kumar A, Prasongsook N, Kasperbauer J, Smallridge RC, Molina JR, Morris JC, Hay I, Thompson G, Grant C, Richards M, Fatourechi V, McIver B, Suman VJ, Lloyd RV, Sebo T, Foote RL, Bible KC 2015 Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer: The Mayo Clinic Experience 15th International Thyroid Congress, Orlando, FL
17. Uruno T, Ogimi Y, Saito F, Masaki C, Akaishi J, Tomoda C, Matsuzu K, Suzuki A, Ohkuwa K, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K 2015 Proposal of a New Staging System and Treatment Algorithm for ATC by Induction Weekly Paclitaxel International Thyroid Conference, Orlando, FL
18. Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA 2016 Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-1066
19. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J 2015 Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736
20. Liu R, Xing M 2016 TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 23:R143-155
21. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY, Clayman GL 2015 Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab 100:E1550-1559
22. Kim TY, Kim KW, Jung TS, Kim JM, Kim SW, Chung KW, Kim EY, Gong G, Oh YL, Cho SY, Yi KH, Kim WB, Park DJ, Chung JH, Cho BY, Shong YK 2007 Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 29:765-772
23. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S 2012 Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36:1247-1254
24. Shi RL, Qu N, Liao T, Wei WJ, Wang YL, Ji QH 2016 The trend of age-group effect on prognosis in differentiated thyroid cancer. Sci Rep 6:27086
25. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
26. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, Anderson WF 2009 Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev 18:1092-1100
27. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C 2008 The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol 214:425-433
28. Zeng Q, ChenGG,Vlantis AC, van HasseltCA2007Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif 40:921-935
29. Carcangiu ML, Steeper T, Zampi G, Rosai J 1985 Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135-158
30. Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A, Piana S 2014 Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014:790834